Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancer.

Gynecologic oncology·2026
Same author

2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines (<u>PART 2</u> - Recommendations on Development & Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies).

Bioanalysis·2024
Same author

Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.

BMC cancer·2022
Same author

T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.

Future oncology (London, England)·2022
Same author

Homologous Recombination Deficiency: Concepts, Definitions, and Assays.

The oncologist·2022
Same author

Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer.

Cancer medicine·2021

Related Experiment Video

Updated: May 5, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

20.2K

Practical guidance for implementing predictive biomarkers into early phase clinical studies.

Matthew J Marton1, Russell Weiner

  • 1Merck Research Laboratories, Clinical Biomarkers and Diagnostics Laboratory, 126 E. Lincoln Avenue, Rahway, NJ 07065, USA.

Biomed Research International
|November 16, 2013
PubMed
Summary

Translating predictive biomarkers into clinical trials presents challenges in sample handling, assay validation, and regulatory compliance. This primer guides drug development teams on implementing biomarkers for patient segmentation and companion diagnostics.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

8.0K
Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

849

Related Experiment Videos

Last Updated: May 5, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

20.2K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

8.0K
Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

849

Area of Science:

  • Biomarker Discovery and Development
  • Clinical Trial Design
  • Companion Diagnostics

Background:

  • Recent U.S. Food and Drug Administration (FDA) coapprovals highlight the importance of predictive biomarkers for targeted therapies.
  • Incorporating predictive biomarkers in clinical studies faces technical, logistical, and regulatory hurdles.
  • A multidisciplinary approach is crucial for successful biomarker translation.

Purpose of the Study:

  • To provide a primer for drug development teams on implementing predictive biomarkers in early clinical trials.
  • To facilitate the subsequent development of companion diagnostics.
  • To address practical issues in using biomarkers for patient segmentation and eligibility determination.

Main Methods:

  • Review of common issues in translating nucleic acid-based assays from discovery to clinic.
  • Focus on key practical considerations for clinical teams.
  • Discussion of challenges in sample collection, assay validation, sample analysis, and regulatory requirements.

Main Results:

  • Identified four broad categories of challenges: sample collection, assay validation, sample analysis, and regulatory requirements.
  • Provided practical guidance for clinical teams planning biomarker implementation.
  • Highlighted the importance of early planning for companion diagnostic development.

Conclusions:

  • Successful translation of predictive biomarkers requires addressing technical, logistic, and regulatory challenges.
  • Early integration of biomarker strategies into clinical trial design is essential.
  • Multidisciplinary collaboration is key to overcoming hurdles in biomarker development and companion diagnostic implementation.